Technology Appraisal Committee Meeting Committee C

Minutes: Confirmed

Date and Time: Wednesday 10 August 2016, 10:00 – 15:00

Venue: National Institute for Health and Care Excellence
Level 1A, City Tower
Piccadilly Plaza
Manchester
M1 4BT

Present:
1. Chair Professor Andrew Stevens Present for all notes
2. Professor Kathryn Abel Present for notes 01 to 11
3. Mr Kamal Balakrishnan Present for all notes
4. Mr Michael Chambers Present for all notes
5. Gail Coster Present for all notes
6. Dr Prithviraj Das Present for notes 01 to 11
7. Professor Rachel Elliott Present for all notes
8. Dr Nigel Langford Present for all notes
9. Vice Chair Professor Eugene Milne Present for all notes
10. Professor Stephen O’Brien Present for all notes
11. Professor Andrew Renehan Present for all notes
12. Dr Peter Selby Present for all notes
13. Prof Matt Stevenson Present for notes 08 to 15
14. Dr Paul Tappenden Present for all notes
15. Robert Walton Present for all notes
16. Dr Judith Wardle Present for all notes

In attendance:

Meindert Boysen Programme Director, National Institute for Health and Care Excellence Present for all notes

Dr Frances Sutcliffe Associate Director, National Institute for Health and Care Excellence Present for all notes

Stephanie Yates Project Manager, National Institute for Health and Care Excellence Present for all notes

Joanne Ekeledo Administrator, National Institute for Health and Care Excellence Present for all notes
Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF inhibitor, nivolumab for treating metastatic, squamous, non-small-cell lung cancer after chemotherapy and nivolumab for previously treated locally advanced or metastatic non-squamous non-small-cell lung cancer.
2. The Chair welcomed Kamal Balakrishnan, Mike Chambers and Dr Prithwiraj Das to their first meeting as a member of the Appraisal Committee

3. Apologies were received from Professor Andrea Manca, Dr Anna O’Neill, David Chandler and Dr Iain Miller.

Any other Business

4. None

Appraisal of certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF inhibitor

Part 1 – Open session

5. The Chair welcomed company representatives from UCB Pharma to the meeting.

6. The Chair asked all Committee members to declare any relevant interests

6.1. Professor Kathryn Abel, Kamal Balakrishnan, Michael Chambers Gail Coster, Dr Prithwiraj Das, Dr Nigel Langford, Professor Eugene Milne, Professor Stephen O’Brien, Professor Andrew Renehan, Dr Peter Selby, Dr Judith Wardle, Robert Walton and Dr Paul Tappenden all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF inhibitor.

6.2. Professor Stephen O’Brien declared a non-personal specific financial interest. Over the past 12 months he have received support from Bristol-Myers Squibb (EHA 2015 and ASH 2015). The support that was required was for ‘booking and payment of reasonable accommodation, meals and travel to attend meetings and conferences’. Over the last 12 months my University and/or NHS Trust has received research funding for clinical trial work from the following companies: Pfizer and Bristol-Myers Squibb. 9.2.1 It was agreed that this declaration would not prevent Professor Stephen O’Brien from participating in this section of the meeting.

6.3. Professor Matt Stevenson is conflicted as he represented the ERG at the meeting.

6.4. Professor Rachel Elliott is conflicted. She declared a personal financial interest.

7. The Chair asked all NICE Staff to declare any relevant interests.

7.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific financial interest.
family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF inhibitor.

8. The Chair asked the ERG to declare their relevant interests.

8.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF inhibitor.

9. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.

10. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

11. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

12. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

13. Discussion on confidential information continued. This information was supplied by the ERG.

14. The Committee continued to discuss the clinical and cost effectiveness of Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF inhibitor.

15. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

Appraisal of nivolumab for treating metastatic, squamous, non-small-cell lung cancer after chemotherapy

Part 1 – Open session

16. The Chair welcomed company representatives from Bristol-Myers Squibb Pharmaceuticals to the meeting.

17. The Chair asked all Committee members to declare any relevant interests.
17.1. Professor Kathryn Abel, Kamal Balakrishnan, Michael Chambers, Gail Coster, Dr Prithwiraj Das, Prof Rachel Elliott, Dr Nigel Langford, Professor Eugene Milne, Professor Stephen O’Brien, Professor Andrew Renehan, Dr Peter Selby, Prof Matt Stevenson, Dr Judith Wardle, Robert Walton and Dr Paul Tappenden all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of nivolumab for treating metastatic, squamous, non-small-cell lung cancer after chemotherapy.

17.2. Professor Stephen O’Brien declared a non-personal specific financial interest. Over the last 12 months he have received support from Bristol-Myers Squibb (EHA 2015 and ASH 2015). The support that was required was for ‘booking and payment of reasonable accommodation, meals and travel to attend meetings and conferences. Over the last 12 months my University and/or NHS Trust has received research funding for clinical trial work from the following companies: Pfizer, Novartis and Bristol-Myers Squibb. Professor O’Brien also stated he does not hold any stock in any of the companies concerned nor any position of employment.

17.2.1 It was agreed that this declaration would not prevent Professor Stephen O’Brien from participating in this section of the meeting.

18. The Chair asked all NICE Staff to declare any relevant interests.

18.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of nivolumab for treating metastatic, squamous, non-small-cell lung cancer after chemotherapy.

19. The Chair asked the ERG to declare their relevant interests.

19.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of nivolumab for treating metastatic, squamous, non-small-cell lung cancer after chemotherapy.

20. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.

21. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

22. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the
confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)" and all public attendees left the meeting.

23. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

24. Discussion on confidential information continued. This information was supplied by the company.

25. The Committee continued to discuss the clinical and cost effectiveness of Nivolumab for treating metastatic, squamous, non-small-cell lung cancer after chemotherapy.

25.1. A vote was taken. The options were:
Option 1: Not to recommend nivolumab for treating locally advanced or metastatic non-squamous non-small cell lung cancer that has progressed after chemotherapy
Option 2: To recommend nivolumab through the Cancer Drugs Fund as an option for treating locally advanced or metastatic non-squamous non-small cell lung cancer that has progressed after chemotherapy in adults only when PD-L1 expression is at least 10%
The Committee voted for Option 2
Details of the result of this discussion will be included in the confirmed version of these minutes, which will be published during the week commencing 12 September 2016 after the publication of all decisions taken at this Committee meeting.

26. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

Appraisal of nivolumab for previously treated locally advanced or metastatic non-squamous non-small-cell lung cancer

Part 1 – Open session

27. The Chair welcomed company representatives from Bristol-Myers Squibb Pharmaceuticals to the meeting.

28. The Chair asked all Committee members to declare any relevant interests

28.1. Professor Kathryn Abel, Kamal Balakrishnan, Michael Chambers, Gail Coster, Prof Rachel Elliott, Dr Nigel Langford, Professor Eugene Milne, Professor Stephen O’Brien, Professor Andrew Renehan, Dr Peter Selby, Prof Matt Stevenson, Dr Judith Wardle, Robert Walton and Dr Paul Tappenden all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of nivolumab
for previously treated locally advanced or metastatic non-squamous non-small-cell lung cancer.

28.2. Dr Prithwiraj Das was absent due to a personal specific financial interest. He works Boehringer Ingelheim Limited. Boehringer Ingelheim is listed as a comparator manufacturer for this appraisal.

29. The Chair asked all NICE Staff to declare any relevant interests.

29.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of nivolumab for previously treated locally advanced or metastatic non-squamous non-small-cell lung cancer.

30. The Chair asked the ERG to declare their relevant interests.

30.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of nivolumab for previously treated locally advanced or metastatic non-squamous non-small-cell lung cancer.

31. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document (ACD) received from consultees, commentators and through the NICE website.

32. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

33. The Chair explained that "representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)" and all public attendees left the meeting.

34. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

35. Discussion on confidential information continued. This information was supplied by the company and the ERG.

36. The Committee continued to discuss the clinical and cost effectiveness of nivolumab for previously treated locally advanced or metastatic non-squamous non-small-cell lung cancer.
36.1. A vote was taken. The options were:
Option 1: Not to recommend nivolumab for treating locally advanced or metastatic non-squamous non-small cell lung cancer that has progressed after chemotherapy
Option 2: To recommend nivolumab through the Cancer Drugs Fund as an option for treating locally advanced or metastatic non-squamous non-small cell lung cancer that has progressed after chemotherapy in adults only when PD-L1 expression is at least 10% 
The Committee voted for Option 2.
Details of the result of this discussion will be included in the confirmed version of these minutes, which will be published during the week commencing 12 September 2016 after the publication of all decisions taken at this Committee meeting.

37. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

Date, time and venue of the next meeting
38. Wednesday 14 September 2016, 10:00 – 17:00 at National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT.